Manitowoc to debut Potain self-erecting crane at Batimat

Manitowoc (MTW) reported Q2 2026 net sales of $594.9 million, up 10.3%, and adjusted EBITDA of $48.9 million, up 85.9%, with margin at 8.2%. Orders rose 56.1% to $708.7 million and backlog was $1,050.1 million. Full-year 2026 guidance was raised: net sales $2.3B-$2.4B and adjusted EBITDA $150M-$170M.

Manitowoc (NYSE:MTW) reported Q2 highlights including aftermarket non-new machine sales up 6% to $172 million, and trailing 12-month aftermarket sales of $706 million. July orders exceeded $200 million. The company cited tariff-related cash refunds of $26 million and raised 2026 guidance to net sales $2.3B-$2.4B and adjusted EBITDA $150M-$170M. Cash was $96M; liquidity $304M.

MANITOWOC CO INC (MTW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 The Manitowoc Company Reports Strong Second-Quarter 2026 Results; Backlog Over $1.0 Billion, Adjusted EBITDA Improved 85.9% From the Prior Year, and Full Year Guidance Raised Second-Quarter 2026 Highlights • Orders of $708.7 million, up 56.1% year-over-year. Backlog

Nvidia's CEO Jensen Huang is proposing to use the company's GPUs as collateral for loans to unlock $500B in financing for AI infrastructure, according to The Motley Fool. Nvidia shares fell 4.5% on Thursday, while the Philadelphia Semiconductor Index dropped nearly 7%. Huang argues that Nvidia's chips retain value longer than typical hardware, citing rising rental prices for older H100 chips.

Eli Lilly's ovarian cancer drug Sofe-M showed a 79% response rate and 100% disease control in new data. The company is evaluating it in a Phase 3 trial with three parts. The drug's safety profile was consistent with known profiles. LLY stock is up 19% year-to-date and 55% over the past 12 months.

Genmab and Incyte will collaborate on a Phase 1/2 trial of petosemtamab with Incyte's KRAS G12D inhibitor and chemotherapy for metastatic colorectal cancer. Incyte will co-fund and supply its drug. The study targets a high-need population, with potential for further development if successful.